Defined Health is a leading business development strategy consulting firm. We’ve been assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.

  • Defined Health has three core lines of business, each focused on helping companies build and strengthen development-stage assets; compounds, portfolios and platforms
  • A key differentiator is the firm’s focus on defining value for early stage compounds as “proof of relevance” (“PoR”), looking beyond mechanistic proof-of-concept to demonstrate clear potential for clinical differentiation and indisputable commercial value
  • Defined Health’s position of trust can be leveraged for the long term, across the continuum of clinical development and “go to” market services
Opportunity Assessments Portfolio and Platform Strategy Identification and Evaluation of In-Licensing Opportunities
  • Validate scientific rationale
  • Position in evolving standard of care
  • Define target patient populations, clinical endpoints and target product profiles
  • Determine payer perspective
  • Assess commercial value
  • Analyze and prioritize pipeline portfolio
  • Identify and assess novel indications for development
  • Prioritize potential indications
  • Define value inflection strategy for clinical candidates
  • Advise on optimal time and stage of development for partnering
  • Advise on partner selection
  • Establish criteria for identifying programs that fit with strategy
  • Identify assets and/or companies that best match criteria
  • Provide deeper analysis of priority targets
  • Identify value inflection points to optimize partnering strategy
  • Leverage extensive industry network to identify potential strategic partners

Our experience means each new project starts from a solid foundation of knowledge – deep in the therapeutic area, wide in application. Over the past two decades, Defined Health has helped to assess the value of many of the industry's headline partnering deals.

We differ from other consulting firms in our unique depth and breadth of experience, in our people, and in the quality of our client interactions. The key to what we have come to call our unconventional insight is our unparalleled therapeutic area experience.


What's New - Clients in the news

27th Annual Cancer Progress Key Conclusions & Recommendations

New Biological Therapies for Asthma: Do the Benefits Justify the Cost?
May 17th, 2016

Aruni S. Arachchige Don, PhD, Consultant, Defined Health Ed Saltzman, President, Defined Health

John Oppenheimer, FACAAI, MD, Director of Clinical Research, Pulmonary and Allergy Associates and Clinical Professor of Medicine, Rutgers University

Connecting Drug Pricing to Value: The Industry's Greatest Challenge
April 4th, 2016

Ed Saltzman, President, Defined Health

Joseph Damond, Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)
Paul K. Gallagher, President, Compass Strategic Consulting, Inc.

Management of Diabetes: Beyond the Insulin and Incretin Pathways
April 4th, 2016

Michael C. Rice, Senior Consultant, Defined Health

Cord Dohrmann, CSO and Board Member, Evotec
Olle Korsgren, Professor, Cell Therapeutics, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital
Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
Matthias Urmann, Associate VP, Diabetes External Innovation, Sanofi

After inflammation, fibrosis: Will biopharma follow nature's lead?
April 4th, 2016

David J. Lomb, PhD, Senior Consultant, Defined Health

Matthias Corbascio, MD, PhD, VP, IsletOne Therapeutics
Donnie McGrath
, MD, MPH, VP, Search and Evaluation, BMS
Elias Papatheodorou, CEO, Genkyotex S.A
Hans T. Schambye, MD, PhD, CEO, Galecto Biotech AB

GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime’s Proprietary Protein Discovery Platform

TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer

Fresh from its AbbVie cancer pact, argenx raises $33M with U.S. investors

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology

Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer

G1 Therapeutics Secures $47 Million Series C Financing

MorphoSys AG Reports Results for the First Three Months of 2016

Heptares And Kymab Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Antibody Therapeutics

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

Bristol-Myers Squibb, Five Prime enter immuno-oncology deal potentially worth over $1.7 billion

Molecular Partners Receives EUROPEAN BIOTECHNICA AWARD 2015

Heron Therapeutics Soars On Pain Drug Success



Pharma CI USA Conference
September 13 - 14, 2016 | Parsippany, NJ

BioPharm America
September 13 - 15, 2016 | Boston, MA

The International Cancer Immunotherapy Conference
September 25 - 28, 2016 New York City

LES Annual Conference
October 23 - 2 6, 2016 Vancouver, BC

November 7 – 9, 2016 Cologne, Germany

SITC 2016
November 9 – 13, 2016 National Harbor, MD|

ASH Annual Meeting
December 3 - 6, 2016 San Diego, CA

Therapeutic Insight by Defined Health Cancer Progress by Defined Health